Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 488

1.

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

Cahill KE, Karimi YH, Karrison TG, Jain N, Green M, Weiner H, Fulton N, Kadri S, Godley LA, Artz AS, Liu H, Thirman MJ, Le Beau MM, McNerney ME, Segal J, Larson RA, Stock W, Odenike O.

Blood Adv. 2020 Feb 25;4(4):599-606. doi: 10.1182/bloodadvances.2019000795.

PMID:
32074275
2.

Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study.

Suh E, Stratton KL, Leisenring WM, Nathan PC, Ford JS, Freyer DR, McNeer JL, Stock W, Stovall M, Krull KR, Sklar CA, Neglia JP, Armstrong GT, Oeffinger KC, Robison LL, Henderson TO.

Lancet Oncol. 2020 Feb 14. pii: S1470-2045(19)30800-9. doi: 10.1016/S1470-2045(19)30800-9. [Epub ahead of print]

PMID:
32066543
3.

Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults.

Wang AY, Muffly LS, Stock W.

JCO Oncol Pract. 2020 Jan 29:JOP1900197. doi: 10.1200/JOP.19.00197. [Epub ahead of print]

PMID:
32048928
4.

Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation: Toxicities with maintenance nivolumab after allogeneic stem cell transplantation.

Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu H.

Biol Blood Marrow Transplant. 2020 Feb 1. pii: S1083-8791(20)30054-9. doi: 10.1016/j.bbmt.2020.01.021. [Epub ahead of print]

PMID:
32018063
5.

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.

Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ.

Blood Adv. 2020 Feb 11;4(3):449-457. doi: 10.1182/bloodadvances.2019000767.

6.

Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.

Kothari S, Artz AS, Lee SM, Fulton N, Park JH, Stock W, Larson RA, Odenike O, Kline J, LaBelle J, Kosuri S, Riedell P, Nakamura Y, Bishop MR, Liu H.

Bone Marrow Transplant. 2020 Jan 28. doi: 10.1038/s41409-020-0798-4. [Epub ahead of print]

PMID:
31992847
7.

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.

Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS.

Blood Adv. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925.

8.

Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.

Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H.

Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25.

PMID:
31790983
9.

Emission factors and composition of PM2.5 from laboratory combustion of five Western Australian vegetation types.

Dong TTT, Stock WD, Callan AC, Strandberg B, Hinwood AL.

Sci Total Environ. 2020 Feb 10;703:134796. doi: 10.1016/j.scitotenv.2019.134796. Epub 2019 Nov 2.

PMID:
31731149
10.

Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.

Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz AS.

Blood Adv. 2019 Nov 26;3(22):3488-3498. doi: 10.1182/bloodadvances.2019000790.

11.

Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Derman BA, Streck M, Wynne J, Christ TN, Curran E, Stock W, Knoebel RW.

Leuk Lymphoma. 2020 Mar;61(3):614-622. doi: 10.1080/10428194.2019.1680839. Epub 2019 Nov 4.

PMID:
31680584
12.

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).

Klepin HD, Ritchie E, Major-Elechi B, Le-Rademacher J, Seisler D, Storrick L, Sanford BL, Marcucci G, Zhao W, Geyer SA, Ballman KV, Powell BL, Baer MR, Stock W, Cohen HJ, Stone RM, Larson RA, Uy GL.

J Geriatr Oncol. 2020 Jan;11(1):107-113. doi: 10.1016/j.jgo.2019.10.002. Epub 2019 Oct 24.

PMID:
31668825
13.

Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.

Balagopal V, Hantel A, Kadri S, Steinhardt G, Zhen CJ, Kang W, Wanjari P, Ritterhouse LL, Stock W, Segal JP.

PLoS One. 2019 Oct 28;14(10):e0224097. doi: 10.1371/journal.pone.0224097. eCollection 2019.

14.

Host specificity in diatom-bacteria interactions alleviates antagonistic effects.

Stock W, Blommaert L, De Troch M, Mangelinckx S, Willems A, Vyverman W, Sabbe K.

FEMS Microbiol Ecol. 2019 Nov 1;95(11). pii: fiz171. doi: 10.1093/femsec/fiz171.

PMID:
31647551
15.

Floral display and habitat fragmentation: Effects on the reproductive success of the threatened mass-flowering Conospermum undulatum (Proteaceae).

Delnevo N, van Etten EJ, Byrne M, Stock WD.

Ecol Evol. 2019 Sep 26;9(19):11494-11503. doi: 10.1002/ece3.5653. eCollection 2019 Oct.

16.

Isolation, characterization, and cross-amplification of 20 microsatellite markers for Conospermum undulatum (Proteaceae).

Delnevo N, Piotti A, van Etten EJ, Stock WD, Byrne M.

Appl Plant Sci. 2019 Aug 9;7(8):e11283. doi: 10.1002/aps3.11283. eCollection 2019 Aug.

17.

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014. Epub 2019 Aug 22. Review.

PMID:
31446198
18.

Thermal Niche Differentiation in the Benthic Diatom Cylindrotheca closterium (Bacillariophyceae) Complex.

Stock W, Vanelslander B, Rüdiger F, Sabbe K, Vyverman W, Karsten U.

Front Microbiol. 2019 Jun 21;10:1395. doi: 10.3389/fmicb.2019.01395. eCollection 2019.

19.

Diatom-Bacteria Interactions Modulate the Composition and Productivity of Benthic Diatom Biofilms.

Koedooder C, Stock W, Willems A, Mangelinckx S, De Troch M, Vyverman W, Sabbe K.

Front Microbiol. 2019 Jun 5;10:1255. doi: 10.3389/fmicb.2019.01255. eCollection 2019.

20.

Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.

van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO.

Blood Adv. 2019 Jun 25;3(12):1858-1867. doi: 10.1182/bloodadvances.2019000200.

21.

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR.

Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.

PMID:
31060979
22.

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):431-440.e13. doi: 10.1016/j.clml.2019.03.015. Epub 2019 Mar 26.

PMID:
31056348
23.

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.

Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1720-1729. doi: 10.1016/j.bbmt.2019.04.020. Epub 2019 Apr 27.

24.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS.

Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28.

25.

Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Curran E, Stock W.

Blood. 2019 Apr 18;133(16):1715-1719. doi: 10.1182/blood-2018-12-852376. Epub 2019 Feb 22. Review.

26.

N-Acyl Homoserine Lactone Derived Tetramic Acids Impair Photosynthesis in Phaeodactylum tricornutum.

Stock F, Syrpas M, Graff van Creveld S, Backx S, Blommaert L, Dow L, Stock W, Ruysbergh E, Lepetit B, Bailleul B, Sabbe K, De Kimpe N, Willems A, Kroth PG, Vardi A, Vyverman W, Mangelinckx S.

ACS Chem Biol. 2019 Feb 15;14(2):198-203. doi: 10.1021/acschembio.8b01101. Epub 2019 Feb 6.

PMID:
30694649
27.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18. Erratum in: Blood. 2019 Sep 26;134(13):1111.

PMID:
30658992
28.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG.

Nat Genet. 2019 Feb;51(2):296-307. doi: 10.1038/s41588-018-0315-5. Epub 2019 Jan 14.

29.

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM.

Am J Hematol. 2019 Apr;94(4):408-416. doi: 10.1002/ajh.25394. Epub 2019 Jan 17.

PMID:
30623490
30.

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.

Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H.

Exp Hematol Oncol. 2019 Jan 3;8:1. doi: 10.1186/s40164-018-0125-6. eCollection 2019.

31.

Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Wynne J, Wright D, Stock W.

Blood Adv. 2019 Jan 8;3(1):96-104. doi: 10.1182/bloodadvances.2018026211. Review.

32.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA.

Blood Adv. 2018 Dec 26;2(24):3608-3617. doi: 10.1182/bloodadvances.2018023689.

33.

Should immunologic strategies be incorporated into frontline ALL therapy?

Rank CU, Stock W.

Best Pract Res Clin Haematol. 2018 Dec;31(4):367-372. doi: 10.1016/j.beha.2018.09.015. Epub 2018 Sep 25. Review.

PMID:
30466749
34.

Treatment of Acute Promyelocytic Leukemia in Adults.

Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA.

J Oncol Pract. 2018 Nov;14(11):649-657. doi: 10.1200/JOP.18.00328. Review.

PMID:
30423270
35.

Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).

Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH.

Pediatr Blood Cancer. 2019 Mar;66(3):e27542. doi: 10.1002/pbc.27542. Epub 2018 Nov 4.

PMID:
30393935
36.

Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.

D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS.

Leuk Lymphoma. 2019 Mar;60(3):629-638. doi: 10.1080/10428194.2018.1493728. Epub 2018 Aug 2.

PMID:
30070150
37.

Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.

Siegel SE, Advani A, Seibel N, Muffly L, Stock W, Luger S, Shah B, DeAngelo DJ, Freyer DR, Douer D, Johnson RH, Hayes-Lattin B, Lewis M, Jaboin JJ, Coccia PF, Bleyer A.

Am J Hematol. 2018 Oct;93(10):1254-1266. doi: 10.1002/ajh.25229. Epub 2018 Sep 3. Review.

38.

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.

Hantel A, Stock W, Kosuri S.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):636-647. doi: 10.1016/j.clml.2018.06.017. Epub 2018 Jun 27. Review.

PMID:
30006258
39.

Environmental drivers and genomic architecture of trait differentiation in fire-adapted Banksia attenuata ecotypes.

He T, Lamont BB, Enright NJ, D'Agui HM, Stock W.

J Integr Plant Biol. 2019 Apr;61(4):417-432. doi: 10.1111/jipb.12697. Epub 2018 Nov 21.

PMID:
29993190
40.

Nematodes stimulate biomass accumulation in a multispecies diatom biofilm.

D'Hondt AS, Stock W, Blommaert L, Moens T, Sabbe K.

Mar Environ Res. 2018 Sep;140:78-89. doi: 10.1016/j.marenvres.2018.06.005. Epub 2018 Jun 5.

PMID:
29891387
41.

Can hydraulically redistributed water assist surrounding seedlings during summer drought?

Muler AL, van Etten EJB, Stock WD, Howard K, Froend RH.

Oecologia. 2018 Jul;187(3):625-641. doi: 10.1007/s00442-018-4158-7. Epub 2018 May 12.

PMID:
29752527
42.

Management of acute lymphoblastic leukemia in young adults.

Muffly LS, Reizine N, Stock W.

Clin Adv Hematol Oncol. 2018 Feb;16(2):138-146. Review.

PMID:
29741514
43.

Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.

Wassermann T, Reimer EK, McKinnon M, Stock W.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02605-17. doi: 10.1128/AAC.02605-17. Print 2018 Jul. No abstract available.

44.

Expanding the toolbox for cryopreservation of marine and freshwater diatoms.

Stock W, Pinseel E, De Decker S, Sefbom J, Blommaert L, Chepurnova O, Sabbe K, Vyverman W.

Sci Rep. 2018 Mar 9;8(1):4279. doi: 10.1038/s41598-018-22460-0.

45.

"Dar"-ing to target CD38 in T-ALL.

Wynne J, Stock W.

Blood. 2018 Mar 1;131(9):948-949. doi: 10.1182/blood-2018-01-826446. No abstract available.

PMID:
29496700
46.

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE.

Clin Cancer Res. 2018 May 15;24(10):2294-2303. doi: 10.1158/1078-0432.CCR-17-2824. Epub 2018 Feb 20.

47.

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.

Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, Reed D, Lewis M, Freyer DR, Shah B, Luger S, Hayes-Lattin B, Jaboin JJ, Coccia PF, DeAngelo DJ, Seibel N, Bleyer A.

JAMA Oncol. 2018 May 1;4(5):725-734. doi: 10.1001/jamaoncol.2017.5305. Review.

PMID:
29450465
48.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.

Cancer. 2018 Apr 15;124(8):1722-1732. doi: 10.1002/cncr.31249. Epub 2018 Jan 30.

49.

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W.

Exp Hematol Oncol. 2018 Jan 11;7:1. doi: 10.1186/s40164-018-0093-x. eCollection 2018.

50.

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.

Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M.

Bone Marrow Transplant. 2018 Apr;53(4):449-456. doi: 10.1038/s41409-017-0019-y. Epub 2018 Jan 12. No abstract available.

Supplemental Content

Support Center